https://prepmedication.com/prep-news The latest developments in HIV prevention (PrEP & PEP): new medications, guideline changes, approvals and access news — medically reviewed and plainly explained. en-us Fri, 17 Jul 2026 09:00:00 GMT 1440 https://prepmedication.com/icon-512.png https://prepmedication.com/prep-news https://prepmedication.com/prep-news prepmed-news-2026-07-checker112 Wed, 15 Jul 2026 09:00:00 GMT Guidance Our free PrEP drug-interaction checker now spans 112 medicines, supplements and recreational drugs — each showing whether it's safe, needs monitoring, or is prohibited with Truvada, Descovy and Apretude, with the mechanism explained. https://prepmedication.com/prep-options prepmed-news-2025-lenacapavir Fri, 20 Jun 2025 09:00:00 GMT Approval Lenacapavir, a long-acting capsid inhibitor given as an injection just twice a year, was approved by the FDA in 2025 for HIV pre-exposure prophylaxis — the longest-acting PrEP yet, with near-100% protection in the PURPOSE trials. https://prepmedication.com/compare-prep-medications prepmed-news-2025-who-lenacapavir Mon, 14 Jul 2025 09:00:00 GMT Guidance The World Health Organization recommended twice-yearly lenacapavir as an additional PrEP option, urging countries to roll it out — a major step for global access to long-acting HIV prevention. https://prepmedication.com/doxy-pep prepmed-news-2024-doxypep Wed, 05 Jun 2024 09:00:00 GMT Guidance The CDC published guidance on Doxy-PEP — a single 200 mg dose of doxycycline within 72 hours after sex to lower the risk of bacterial STIs for gay/bisexual men and transgender women. https://prepmedication.com/how-to-get-prep prepmed-news-2023-uspstf Tue, 22 Aug 2023 09:00:00 GMT Access The US Preventive Services Task Force gave PrEP its top "A" rating, meaning most insurers and Medicaid must cover the medication and its follow-up visits and labs with no out-of-pocket cost. https://prepmedication.com/apretude-side-effects prepmed-news-2021-apretude Mon, 20 Dec 2021 09:00:00 GMT Approval Apretude became the first long-acting injectable PrEP — an injection every 2 months instead of a daily pill — approved for all populations at risk, including cisgender women.